Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects With Severe Atopic Dermatitis

NCT03646604 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03646604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03646604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects With Severe Atopic Dermatitis
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2019
Completion date
August 29, 2024
Enrollment
35 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis